|
Inhibition
of Proliferation of Estrogen-Dependent and Estrogen-Independent
Human Breast Cancer Cells Treated with Carotenoids or Retinoids.
Prakash
P, Russell RM, Krinsky NI. In Vitro J Nutr. 2001;131:1574-80.
Immunohistochemical
detection of ERbeta in breast cancer: towards more detailed
receptor profiling?
Skliris
GP, Carder PJ, Lansdown MR, Speirs V. Br J Cancer. 2001;84:1095-8.
Prognostic
factors in women with breast cancer: distribution by socioeconomic
status and effect on differences in survival.
Thomson
CS, Hole DJ, Twelves CJ, Brewster DH, Black RJ. J Epidemiol
Community Health. 2001;55:308-15.
HER2:
the neu prognostic marker for breast cancer.
Tsongalis
GJ, Ried A Jr. Crit Rev Clin Lab Sci. 2001;38:167-82.
Predicting
Axillary Nodal Positivity in 2282 Patients with Breast Carcinoma.
Silverstein
MJ, Skinner KA, Lomis TJ. World J Surg. 2001;25:767-772.
Decreased
expression of estrogen receptor beta protein in proliferative
preinvasive mammary tumors.
Roger
P, Sahla ME, Makela S, Gustafsson JA, Baldet P, Rochefort
H. Cancer Res. 2001;61:2537-41.
Prognostic
and predictive factors in primary breast cancer and their
role in patient management: The Nottingham Breast Team.
Rampaul
RS, Pinder SE, Elston CW, Ellis IO. Eur J Surg Oncol. 2001;27:229-38.
Tumor
Suppressor p53 Binding Protein 1 (53BP1) Is Involved in DNA
Damage-signaling Pathways.
Rappold
I, Iwabuchi K, Date T, Chen J. J Cell Biol. 2001;153:613-20.
Cadherins
as predictive markers of nodal metastasis in breast cancer.
Madhavan
M, Srinivas P, Abraham E, et al. Mod Pathol. 2001;14:423-7.
Internal
mammary lymph node drainage patterns in patients with breast
cancer documented by breast lymphoscintigraphy.
Byrd
DR, Dunnwald LK, Mankoff DA, et al. Ann Surg Oncol. 2001;8:234-40.
Differences
in estrogen receptor status, HER2, and p53 comparing metachronous
bilateral breast carcinoma.
Matsuo
K, Fukutomi T, Tsuda H, Akashi-Tanaka S, Shimizu C, Hasegawa
T. J Surg Oncol. 2001;77:31-4.
Resveratrol
inhibits human breast cancer cell growth and may mitigate
the effect of linoleic acid, a potent breast cancer cell stimulator.
Nakagawa
H, Kiyozuka Y, Uemura Y, et al. J Cancer Res Clin Oncol.
2001;127:258-64.
Automated
immunofluorometric assay for MUC1.
Norum
LF, Nilsson O, Nustad K. Tumour Biol. 2001;22:169-75.
A
practical and easy method to locate the first three internal
mammary lymph node-bearing areas.
Marks
LB, Bentel GC, Hardenbergh PH, Lind PA, Prosnitz LR. Int J
Radiat Oncol Biol Phys. 2001;50:421-5.
Subcellular
localization and distribution of the breast cancer resistance
protein transporter in normal human tissues.
Maliepaard
M, Scheffer GL, Faneyte IF, et al. Cancer Res. 2001;61:3458-64.
Functional
evaluation of plasmin formation in primary breast cancer.
Chappuis
PO, Dieterich B, Sciretta V, et al. J Clin Oncol. 2001;19:2731-8.
S-phase
fraction and dna ploidy in 633 t1t2 breast cancers: a standardized
flow cytometric study.
Chassevent
A, Jourdan ML, Romain S, et al. Clin Cancer Res. 2001;7:909-17.
Differential
screening and mass mapping of proteins from premalignant and
cancer cell lines using nonporous reversed-phase HPLC coupled
with mass spectrometric analysis.
Chong
BE, Hamler RL, Lubman DM, Ethier SP, Rosenspire AJ, Miller
FR. Anal Chem. 2001;73:1219-27.
Comparative
analysis of micrometastasis to the bone marrow and lymph nodes
of node-negative breast cancer patients receiving no adjuvant
therapy.
Braun
S, Cevatli BS, Assemi C, et al. Journal
of Clinical Oncology. 19(5):1468-1475, 2001 Mar 1.
Axillary
Lymph Node Staging in Breast Cancer by 2-Fluoro-2-deoxy-D-glucose-Positron
Emission Tomography: Clinical Evaluation and Alternative Management.
Greco
M, Crippa F, Agresti R, et al. J
Natl Cancer Inst. 2001;93:630-635.
Prognostic
impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup
of node-negative breast cancer patients with low histological
grade tumors.
Gaci
Z, Bouin-Pineau MH, Gaci M, Daban A, Ingrand P, Metaye T.
Int J Oncol. 2001;18:793-800.
Prognosis
and treatment of patients with breast tumors of one centimeter
or less and negative axillary lymph nodes.
Fisher
B, Dignam J, Tan-Chiu E, et al. J Natl Cancer Inst. 93(2):112-120,
2001 Jan 17.
BAG-1:
A novel biomarker predicting long-term survival in early-stage
breast cancer.
Turner
BC, Krajewski S, Krajewska M, et al. Journal of Clinical Oncology.
19(4):992-1000, 2001 Feb 15.
Preoperative
assessment of prognostic factors in breast cancer.
Denley
H, Pinder SE, Elston CW, Lee AHS, Ellis IO. Journal of Clinical
Pathology. 54(1):20-24, 2001 Jan.
Cyclin
E immunoexpression in breast ductal carcinoma: Pathologic
correlations and prognostic implications.
Donnellan
R, Kleinschmidt I, Chetty R. Human Pathology. 32(1):89-94,
2001 Jan.
Prognostic
and predictive significance of ErbB-2 breast tumor levels
measured by enzyme immunoassay.
Eppenberger-Castori
S, Kueng W, Benz C, et al. Journal of Clinical Oncology. 19(3):645-656,
2001 Feb 1.
Prognosis
and treatment of patients with breast tumors of one centimeter
or less and negative axillary lymph nodes.
Fisher
B, Dignam J, Tan-Chiu E, et al. J Natl Cancer Inst. 93(2):112-120,
2001 Jan 17.
Thrombospondin-l
and-2 in node-negative breast cancer: Correlation with angiogenic
factors, p53, cathepsin D, hormone receptors and prognosis.
Gasparini
G, Toi M, Biganzoli E, et al. Oncology. 60(1):72-80,
2001.
Simultaneous
immunohistochemical detection of tumor cells in lymph nodes
and bone marrow aspirates in breast cancer and its correlation
with other prognostic factors.
Gerber
B, Krause A, Muller H, et al. Journal of Clinical Oncology.
19(4):960-971, 2001 Feb 15.
New
prognostic factors for breast cancer recurrence [Review].
Isaacs
C, Stearns V, Hayes DF. Seminars in Oncology. 28(1):53-67,
2001 Feb.
Prognostic
significance of the number of bone scan abnormalities at the
time of initial bone metastatic recurrence in breast carcinoma.
Jacobson
AF, Shapiro CL, Van den Abbeele AD, Kaplan WD. Cancer Cytopathology.
91(1):17-24, 2001 Jan 1.
c-erbB-2
Positivity is a factor for poor prognosis in breast cancer
and poor response to hormonal or chemotherapy treatment in
advanced disease.
Jukkola
A, Bloigu R, Soini Y, Savolainen ER, Holli K, Blanco G. European
Journal of Cancer. 37(3):347-354, 2001 Feb.
HER-2/neu
oncogene expression in advanced breast cancer.
Krogerus
LA, Leivonen M. Cancer Detection & Prevention. 25(1):1-7,
2001.
Omission
of histologic grading from clinical decision making may result
in overuse of adjuvant therapies in breast cancer: Results
from a nationwide study.
Lundin
J, Lundin M, Holli K, et al. Journal of Clinical Oncology.
19(1):28-36, 2001 Jan 1.
Genetic
variation in the tumor necrosis factor-alpha promoter region
and in the stress protein hsp70-2 - Susceptibility and prognostic
implications in breast carcinoma.
Mestiri
S, Bouaouina N, Ben Ahmed S, et al. Cancer. 91(4):672-678,
2001 Feb 15.
Expression
of cell-cycle regulator p27 is correlated to the prognosis
and ER expression in breast carcinoma patients.
Nohara
T, Ryo T, Iwamoto S, Gon G, Tanigawa N. Oncology. 60(1):94-100,
2001.
Prediction
of node-negative breast cancer outcome by histologic grading
and S-phase analysis by flow cytometry - An Eastern Cooperative
Oncology Group study (2192).
Page
DL, Gray R, Allred CC, et al. American Journal of Clinical
Oncology-Cancer Clinical Trials. 24(1):10-18, 2001 Feb.
Tumor
biology and prognosis in black breast cancer patients: A review
[Review].
Rose
DP, Royak-Schaler R. Cancer Detection & Prevention. 25(1):16-31,
2001.
Highly
sensitive immunohistological study for detection of estrogen
receptor in human breast cancer.
Sumiyoshi
Y, Shirakusa T, Yamashita Y, Maekawa T, Sakai T, Kikuchi M.
Journal of Surgical Oncology. 76(1):13-18, 2001 Jan.
Identification
of CGA as a novel estrogen receptor-responsive gene in breast
cancer: An outstanding candidate marker to predict the response
to endocrine therapy.
Bieche
I, Parfait B, Le Doussal V, et al. Cancer Research. 61(4):1652-1658,
2001 Feb 15.
Overexpression
of the steroid receptor coactivator AIB1 in breast cancer
correlates with the absence of estrogen and progesterone receptors
and positivity for p53 and HER2/neu.
Bouras
T, Southey MC, Venter DJ. Cancer Research. 61(3):903-907,
2001 Feb 1.
Microsomal
epoxide hydrolase expression as a predictor of tamoxifen response
in primary breast cancer: A retrospective exploratory study
with long-term follow-up.
Fritz
P, Murdter TE, Eichelbaum M, Siegle I, Weissert M, Zanger
UM. Journal of Clinical Oncology. 19(1):3-9, 2001 Jan 1.
Highly
sensitive immunohistological study for detection of estrogen
receptor in human breast cancer.
Sumiyoshi
Y, Shirakusa T, Yamashita Y, Maekawa T, Sakai T, Kikuchi M.
Journal of Surgical Oncology. 76(1):13-18, 2001 Jan.
Study
of interlaboratory reliability and reproducibility of estrogen
and progesterone receptor assays in Europe - Documentation
of poor reliability and identification of insufficient microwave
antigen retrieval time as a major contributory element of
unreliable assays.
Rhodes
A, Jasani B, Balaton AJ, et al. American Journal of Clinical Pathology. 115(1):44-58, 2001 Jan.
Simultaneous
immunohistochemical detection of tumor cells in lymph nodes
and bone marrow aspirates in breast cancer and its correlation
with other prognostic factors.
Gerber
B, Krause A, Muller H, et al. Journal of Clinical Oncology.
19(4):960-971, 2001 Feb 15.
Molecular
Biomarkers for Breast Cancer Prognosis: Coexpression of c-erbB-2
and p53.
Beenken
SW, Grizzle WE, Crowe DR, et al. Ann Surg. 2001;233:630-8.
Early
distant relapse in "node-negative" breast cancer
patients is not predicted by occult axillary lymph node metastases,
but by the features of the primary tumour.
Colpaert
C, Vermeulen P, Jeuris W, et al. J Pathol. 2001;193:442-9.
Prognosis
of breast cancers detected in women receiving hormone replacement
therapy.
Delgado
RC, Lubian Lopez DM. Maturitas. 2001;38:147-56.
Breast
Cancer: Assessing the Use of Routine Pelvic CT in Patient
Evaluation.
Drotman
MB, Machnicki SC, Schwartz LH, Winston CB, Yoo HH, Panicek
DM. AJR Am J Roentgenol. 2001;176:1433-1436.
Fifteen-year
prognostic discriminants for invasive breast carcinoma.
Fisher
ER, Anderson S, Tan-Chiu E, Fisher B, Eaton L, Wolmark N.
Cancer. 2001;91:1679-87.
Effect
of pregnancy on overall survival after the diagnosis of early-stage
breast cancer.
Gelber
S, Coates AS, Goldhirsch A, et al. J Clin Oncol. 2001;19:1671-5.
Amplification
of growth regulatory genes in intraductal breast cancer is
associated with higher nuclear grade but not with the progression
to invasiveness.
Glockner
S, Lehmann U, Wilke N, Kleeberger W, Langer F, Kreipe H. Lab
Invest. 2001;81:565-71.
Prediction
of lymph node status by analysis of prognostic factors and
possible indications for elective axillary dissection in T1
breast cancers.
Guarnieri
A, Neri A, Correale PP, et al. Eur J Surg. 2001;167:255-9.
Is
the UICC pathological node status system useful? Comparison
with the Japanese Breast Cancer Society pathological node
status system.
Hayashi
M, Sakamoto G, Akiyama F, Kasumi F, Hatakeyama K. J Surg Oncol.
2001;76:255-60.
Overexpression
of the steroid receptor coactivator AIB1 in breast cancer
correlates with the absence of estrogen and progesterone receptors
and positivity for p53 and HER2/neu.
Bouras
T, Southey MC, Venter DJ. Cancer Research. 61(3):903-907,
2001 Feb 1.
Prognostic
and predictive significance of ErbB-2 breast tumor levels
measured by enzyme immunoassay.
Eppenberger-Castori
S, Kueng W, Benz C, et al. Journal of Clinical Oncology. 19(3):645-656,
2001 Feb 1.
c-erbB-2
Positivity is a factor for poor prognosis in breast cancer
and poor response to hormonal or chemotherapy treatment in
advanced disease.
Jukkola
A, Bloigu R, Soini Y, Savolainen ER, Holli K, Blanco G. European
Journal of Cancer. 37(3):347-354, 2001 Feb.
Response
to cyclophosphamide, methotrexate, and fluorouracil in lymph
node-positive breast cancer according to HER2 overexpression
and other tumor biologic variables.
Menard
S, Valagussa P, Pilotti S, et al. Journal of Clinical Oncology.
19(2):329-335, 2001 Jan 15.
The
collaboration of both humoral and cellular HER-2/neu-targeted
immune responses is required for the complete eradication
of HER-2/neu-expressing tumors.
Reilly
RT, Machiels JPH, Emens LA, et al. Cancer Research. 61(3):880-883, 2001 Feb 1.
|
